Hengrui Medicine: Injection SHR-A2009 approved for clinical trials of drugs.

Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration for the injection SHR-A2009. Clinical trials will be conducted soon. The injection SHR-A2009 is a monoclonal antibody drug conjugate targeting HER3, and no similar drugs have been approved for marketing globally. As of now, the cumulative research and development investment in the injection SHR-A2009 project is approximately 198 million yuan.